Robert Eisenbach

Cooley advised Otsuka Pharmaceutical, a total healthcare company focused on each individual’s potential to enhance their well-being, on its global strategic collaboration with Harbour BioMed to advance BCMAxCD3 bispecific T-cell engagers for treating autoimmune diseases.

Cooley advised Sirius Therapeutics, a clinical-stage biotech company developing innovative small interfering RNA (siRNA) therapies for global markets, on its strategic partnership to develop and commercialize siRNA therapies with CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases.

Cooley advised Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma), a global pharmaceutical company focused on scientific and technological innovation, on its exclusive license agreement with Merck KGaA, Darmstadt, Germany for the commercialization in mainland China of SHR7280, an oral small-molecule gonadotropin-releasing hormone receptor antagonist, for indications including medical-assisted reproduction and gynecology.

Cooley advised Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma), a global pharmaceutical company focused on scientific and technological innovation, on its exclusive license agreement with Merck (NYSE: MRK), known as MSD outside of the US and Canada, for HRS-5346, an investigational oral small molecule lipoprotein(a), or Lp(a), inhibitor currently being evaluated in a phase 2 clinical trial in China.

Cooley advised Kim Kardashian, an American media personality, socialite and businesswoman, on SKIMS’ acquisition of SKKN by Kim, a beauty, skincare, and fragrance brand she founded, including the 20% stake held by Coty.